Therapy News and Research

RSS

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

The U.S. Food and Drug Administration today approved Amyvid (Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

11 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

Delcath, NKI-AVL enter initial launch and training agreement for CHEMOSAT system

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands.

10 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

More than 60% of breast cancer survivors report post-treatment complications

More than 60 percent of breast cancer survivors report at least one treatment-related complication even six years after their diagnosis, according to a new study led by a researcher from the Perelman School of Medicine at the University of Pennsylvania.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

Mayo Clinic introduces Breast Cancer Genome Guided Therapy Study

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors.

10 Apr 2012

UofL wins NIH grant for cardiac clinical research center

During his 18-year tenure at UofL, Dr. Roberto Bolli has generated more than $100 million in grants for basic research from the NIH. Today, Bolli joined with University of Louisville President James R. Ramsey to announce a new NIH grant he has won for clinical research, a seven-year, $3.4 million grant from the National Heart, Lung and Blood Institute to establish one of seven regional centers across the United States in the Cardiac Cell Therapy Research Network.

10 Apr 2012

ReCor Medical provides updated data from REDUCE Percutaneous Renal Denervation System study

ReCor Medical, an emerging medical device company, disclosed today updated data for the REDUCE First-In-Man clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation.

10 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

First Choice acquires FCMG

First Choice Healthcare Solutions, Inc. today announced its acquisition of First Choice Medical Group of Brevard, LLC, a multi-specialty medical group practice including orthopedics (both operative and non-operative), sports medicine, pain management and neurology located in Melbourne, Fla.

10 Apr 2012

States roundup: Aetna goes ahead with small biz coverage hike; 1.2M Texas kids without insurance; Legal immigrants join Mass. health plan

Despite criticism from the state insurance commissioner and several statewide consumer groups, Aetna said Thursday it's going ahead with a recent hike in health care premiums for small businesses. Aetna's new increases, which average 8 percent annually and took effect April 1, were deemed "unreasonable" this week by state Department of Insurance Commissioner David Jones.

10 Apr 2012

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

9 Apr 2012

Synapse Medical acquires another MicroThermX Microwave Ablation System

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold an additional MicroThermX Microwave Ablation System to Synapse Medical Ltd.

9 Apr 2012

Delivering chemotherapy drugs with nanobubbles more deadly to cancer cells

Using light-harvesting nanoparticles to convert laser energy into "plasmonic nanobubbles," researchers at Rice University, the University of Texas MD Anderson Cancer Center and Baylor College of Medicine (BCM) are developing new methods to inject drugs and genetic payloads directly into cancer cells.

9 Apr 2012

Chemotherapy based on individual genomes and genomes of tumors

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors.

9 Apr 2012

Bioness commences StimRouter Neuromodulation System study for chronic peripheral nerve pain

Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.

9 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

Inflammasome involved in regulating Age-Related Macular Degeneration

Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration.

9 Apr 2012